Shanghai Institute of Materia Medica
http://english.simm.cas.cn/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shanghai Institute of Materia Medica
Venture Capital, Private Equity Investors Keep Pumping Cash Into China CGT Space
Among the latest financing deals, advanced therapeutics such as cell and gene therapies (CGT) continued enjoying the spotlight from venture capital and private equity investors in China. Meanwhile, small molecules with novel mechanism of action such as molecule glue stood out from their peers to win investors’ favor.
Junshi’s COVID Antiviral Superior To Paxlovid? Some Caveats Unveiled
Unexpected protocol changes and a single-blind design for a Phase III head-to-head trial seem to have played to the advantage of Junshi’s oral derivative of Gilead’s antiviral remdesivir in COVID-19.
China’s Home-Grown Oral COVID Antiviral Eyes Wider Population
Simcere is weighing options for SIM0417 in a Phase I trial in China as the first major domestically-developed potential rival to Pfizer’s oral COVID-19 antiviral Paxlovid. The study is likely to include wider patient groups ranging from those without symptoms to severe patients.
Coronavirus Update: Paxlovid Moves Towards EU Approval, Moderna Targets Omicron
Pfizer gets European Commission approval for Paxlovid after a positive CHMP opinion, while Moderna started a Phase II study of its Omicron-specific vaccine candidate. Meanwhile, China's Junshi enters into a new oral antiviral collaboration while Daiichi Sankyo investigates its mRNA vaccine contender as a booster shot.
Company Information
- Industry
- Academic and Research Institutions
- Other Names / Subsidiaries
-
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice